Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.44 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | LOX | P28300 | 1/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.40 |
| ▸ | ACVR2A | P27037 | 2/20 | 0.40 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30626327 | 0.82 | LOX (0.55) | S1PR1DYRK1ASLC13A5CHRNA7CNR1 | |
| SCHEMBL16116782 | 0.82 | LOX (0.55) | S1PR1DYRK1ASLC13A5CHRNA7CNR1 | |
| SCHEMBL15889947 | 0.81 | S1PR1 (0.68) | S1PR1DYRK1ALOXLOXL2AAK1 | |
| SCHEMBL22283952 | 0.81 | HSD17B1 (0.49) | S1PR1DYRK1ASLC13A5CHRNA7CNR1 | |
| SCHEMBL13036116 | 0.80 | DYRK1A (0.55) | S1PR1DYRK1ASLC13A5CHRNA7CNR1 | |
| SCHEMBL22214071 | 0.80 | TRPA1 (0.46) | S1PR1DYRK1ASLC13A5CHRNA7CNR1 | |
| SCHEMBL22313787 | 0.80 | SLC13A5 (0.45) | S1PR1SLC13A5CHRNA7CNR1LOX | |
| SCHEMBL17493530 | 0.79 | NR4A2 (0.47) | SLC13A5 | |
| SCHEMBL22797191 | 0.79 | GABRG2 (0.53) | CYP2A6 | |
| SCHEMBL22797722 | 0.78 | PDK1 (0.42) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230025130-A1 | METHODS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11129829-B2 | Methods for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20200390765-A1 | METHODS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129829-B2 | Methods for modulating splicing | RBM17, SNRPE, SNRPB2 | S1PR1 2675/4885DYRK1A 4470/4885SLC13A5 4302/4885 |
| US-20230025130-A1 | METHODS FOR MODULATING SPLICING | RBM17, SNRPE, SNRPB2 | S1PR1 2675/4885DYRK1A 4470/4885SLC13A5 4302/4885 |
| US-20200390765-A1 | METHODS FOR MODULATING SPLICING | RBM17, SNRPE, SNRPB2 | S1PR1 2675/4885DYRK1A 4470/4885SLC13A5 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.